FDA OMHHE Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH) (U01) Clinical Trials Optional
ID: 356052Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$3M - $3M

Eligible Applicants

Unrestricted

Funding Category

Consumer Protection

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356052
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH), which will be administered as a cooperative agreement (U01). This initiative aims to enhance minority health and health equity through research, outreach, and communication efforts, while also providing training and mentorship for diverse students, fellows, and researchers. The program is critical for advancing health equity and addressing disparities in health outcomes among racial and ethnic minorities. Interested applicants can apply for a funding amount of $3 million, with an expected six awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. The opportunity is set for the fiscal year 2025, with no cost-sharing or matching requirements.

    Point(s) of Contact
    Terrin Brown Grantor
    (240) 402-7610
    terrin.brown@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Health Equity Innovation Award (U01) to fund innovative research aimed at enhancing minority health and advancing health equity objectives. This funding opportunity focuses on proposals that promote diversity in clinical trials, improve data availability on diverse populations, and amplify the voices of underrepresented patient groups. With an award ceiling of $1 million and a floor of $250,000, the FDA anticipates making four awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01)," aimed at advancing minority health and health equity objectives. This cooperative agreement seeks innovative research proposals that enhance diversity in clinical trials, improve data availability on diverse populations, and amplify diverse patient perspectives and needs. The initiative is crucial for addressing disparities in health outcomes and ensuring equitable representation in health research. Interested applicants can apply for a funding amount of $1 million, with an expected four awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610. The opportunity is set for the fiscal year 2025 and was last updated on August 14, 2024.
    FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "FDA OMHHE Convener for Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH)." This initiative aims to support a convener for the REACH consortium, which will consist of 5-8 multi-project cooperative agreement awardees focused on advancing minority health and health equity by facilitating communication, research, and collaboration on health issues disproportionately affecting racial and ethnic minority populations. The selected convener will be responsible for coordinating data integration, analysis, and visualization, as well as managing workshops and collaborations among REACH investigators. Interested applicants, particularly small businesses, can reach out to Shashi Malhotra at shashi.malhotra@fda.hhs.gov or call 240-402-7592 for further details. The estimated synopsis post date is January 3, 2023, with a closing date anticipated on March 3, 2023, and the funding opportunity falls under the category of discretionary grants with no cost-sharing requirements.
    Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Transformative Research to Address Health Disparities and Advance Health Equity" initiative, aimed at funding innovative research that addresses social determinants of health (SDOH) to significantly reduce health disparities and promote equity among underserved populations. This cooperative agreement seeks projects that demonstrate a compelling potential to produce major impacts on health equity, with a maximum funding amount of $500,000 per year for a project duration of up to five years, and a total funding commitment of approximately $3 million for 4-6 awards. Applications must include a Plan for Enhancing Diverse Perspectives (PEDP) and are expected to engage in community partnerships, with submission deadlines starting from January 29, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-25-003.html.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This cooperative agreement aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) initiatives by promoting education, outreach, and public awareness regarding the use and potential risks associated with skin lightening products, such as hydroquinone. The funding is crucial for developing innovative, community-based strategies that will strengthen the scientific foundation for public health education on this topic. Interested applicants can apply for a funding amount of $250,000, with the opportunity forecasted for fiscal year 2025. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610.
    Notice of Intent to Publish a Funding Opportunity Announcement for Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the initiative titled "Transformative Research to Address Health Disparities and Advance Health Equity" (U01 Clinical Trial Optional). This funding opportunity aims to foster innovative research projects that address significant health disparities and promote health equity, encouraging collaborations among researchers. The estimated total program funding is $3 million, with an award ceiling of $500,000 per project, and the application period is expected to open on December 10, 2024, with a closing date of February 28, 2025. Interested applicants should prepare to submit their proposals by the deadline, as the estimated award date is September 1, 2025.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a grant opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This initiative aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) efforts by funding research and community-based strategies that promote education and public awareness regarding the risks associated with over-the-counter skin lightening products containing hydroquinone and/or mercury. The grant, which has a fixed award amount of $250,000, is open to unrestricted applicants and is part of the fiscal year 2024 funding cycle. Interested parties can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities," aimed at supporting intervention research to improve health outcomes among minority populations affected by health disparities. The initiative seeks projects that investigate the influence of structural racism and discrimination on health determinants, promote multidisciplinary collaboration, and utilize diverse data sources for comprehensive analysis. With a funding ceiling of $500,000, the application deadline is set for January 7, 2026, and interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further details.
    Notice of Intent to Publish a Funding Opportunity Announcement for NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the initiative titled "NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use," aimed at addressing HIV-related health disparities in underserved racial and/or ethnic populations. This funding opportunity will solicit research applications that propose novel approaches to tackle these critical health issues, with a focus on fostering meaningful collaborations among applicants. The estimated total program funding for this initiative is $2,000,000, with the NOFO expected to be published in Summer 2025 and applications due in Winter 2025. Interested researchers should prepare to submit their proposals by the anticipated deadlines, with awards expected to be made by July 1, 2026.